Hospira gets FDA warning letter about Australia plant

SHARE Hospira gets FDA warning letter about Australia plant

Hospira Inc. has received a warning letter from the U.S. Food and Drug Administration related to an inspection of the drugmaker’s operations at an Australian plant.

The FDA letter, which Hospira said it received Monday, said the company had not adequately fixed production problems found during an inspection of the Mulgrave, Australia, plant between Feb. 24 and March 1. The plant makes specialty injectable drugs.

“The company is evaluating what corrective actions may be required, and associated costs may be incurred, to address the matters raised in the warning letter,” Hospira said in a statement. “The company takes this matter seriously, and intends to respond fully and in a timely manner to the FDA’s warning letter.”

Lake Forest-based Hospira said it doesn’t expect the warning letter will affect its 2014 financial guidance.

The Latest
Counsell had high praise for the exciting young player at the winter meetings this week.
Dosunmu’s efforts in the Bulls’ previous two games were pivotal in securing the team’s first winning streak this season. He averaged 14.5 points, 4.5 assists, three rebounds and 2.5 steals.
The NBA trade deadline is Feb. 8. The majority of the league becomes tradable Dec. 15, when free-agent contracts signed in the summer can be moved. That means LaVine might have played his final game for the Bulls.
San Diego received right-handed pitchers Michael King, Jhony Brito, Randy Vásquez and Drew Thorpe along with catcher Kyle Higashioka. In addition to Soto, the Yankees get Gold Glove center fielder Trent Grisham.